Analyzing and resolving a communication crisis in Dhaka textiles LTD.pptx
ARNI ARTICAL DONE.pptx
1. ARNI reduces renal outcomes in
patients with HFmrEF/HFpEF
HFmrEF: Heart Failure with mildly reduced Ejection
Fraction
HFpEF: Heart Failure with preserved Ejection Fraction
2. Introduction
The study aimed to assess sacubitril/valsartan's impact on
kidney outcomes in PARAGLIDE-HF and PARAGON-HF
trials for patients with HFmrEF/HFpEF.
3. Methodology
.
M
e
t
h
o
d
o
l
o
g
y
Pooled analysis of PARAGLIDE-HF and PARAGON-HF trials (n=5262 participants).
PARAGLIDE-HF (n=466) included high-risk patients within 30 days of worsening HF.
PARAGON-HF (n=4796) had clinically stable patients with treatment run-in before
randomization.
Follow-up duration: PARAGLIDE-HF 0.4 years, PARAGON-HF 2.9 years.
4. RESULTS
Sacubitril/valsartan
decreased renal risk
vs. valsartan (HR:
0.60; 95%CI: 0.44-
0.83; P=0.002
Positive effects
seen within 2
months (day 58).
Consistent kidney
effect across
different patient
groups and trials
Slowed kidney decline
more than valsartan in
both trials: PARAGON-
HF (0.6
mL/min/1.73m²),
PARAGLIDE-HF (4.2
mL/min/1.73m²).
5. Conclusion
Combined analysis of PARAGLIDE-HF and PARAGON-HF trials:
sacubitril/valsartan lowers kidney risks in HFmrEF/HFpEF patients,
benefiting both hospitalized and ambulatory cases. Quick renal
improvements seen after treatment. Slows eGFR decline compared to
valsartan.
